Cargando…
Development and Validation of a Simulation Model–Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions
There is a need for industry-independent decision tools that integrate clinicopathologic features, comorbidities, and genomic information for women with node-negative, invasive, hormone receptor–positive, human epidermal growth factor receptor-2–negative (early-stage) breast cancer. METHODS: We adap...
Autores principales: | Jayasekera, Jinani, Sparano, Joseph A., O'Neill, Suzanne, Chandler, Young, Isaacs, Claudine, Kurian, Allison W., Kushi, Lawrence, Schechter, Clyde B., Mandelblatt, Jeanne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425835/ https://www.ncbi.nlm.nih.gov/pubmed/34251881 http://dx.doi.org/10.1200/JCO.21.00651 |
Ejemplares similares
-
Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer
por: Jayasekera, Jinani, et al.
Publicado: (2019) -
Simulation modeling of breast cancer endocrine therapy duration by patient and tumor characteristics
por: Chandler, Young, et al.
Publicado: (2021) -
Reassessing the Benefits and Harms of Risk-Reducing Medication Considering the Persistent Risk of Breast Cancer Mortality in Estrogen Receptor–Positive Breast Cancer
por: Jayasekera, Jinani, et al.
Publicado: (2023) -
A scoping review of interactive and personalized web-based clinical tools to support treatment decision making in breast cancer
por: Zhao, Amy, et al.
Publicado: (2021) -
Reflecting on 20 years of breast cancer modeling in CISNET: Recommendations for future cancer systems modeling efforts
por: Trentham-Dietz, Amy, et al.
Publicado: (2021)